Storm clouds gather for biotech flotations
Only seven drug developers managed to float on Western exchanges in the third quarter, and new issues in October have struggled, with Biontech the latest example.
2017 rewrites the record books as venture funding accelerates
In terms of venture financing, activity in 2017 outpaced that at the height of the biotech boom in 2015, with 68 biotechs attracted rounds of $50m or more.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.